Results 261 to 270 of about 49,482 (293)

Daratumumab combined with anti-CD20 therapy in pediatric and adult refractory idiopathic nephrotic syndrome: single-center experience. [PDF]

Front Immunol
Naciri Bennani H, Sandaye T, Charroyer Q, Etangsale A, Vacher Coponat H, Julien M, Mear V, Dunand O, Di Ascia L.   +8 more
europepmc   +1 more source

Duales Targeting von malignen B-Zellen mit einem bispezifischen chimären Antigen-Rezeptor (CAR) zur Erkennung von Antigen-Verlustvarianten [PDF]

, 2016
Martyniszyn, Alexandra
core  

'Immune reset plus': the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases. [PDF]

Front Immunol
Gaspal F, Narendran P, Ng STH, Price MJ, Wraith DC.   +4 more
europepmc   +1 more source

CD5⁺ primary hepatosplenic large B-cell lymphoma and rhupus syndrome in a patient: a case of concurrent diagnosis? [PDF]

Discov Oncol
Lin S, Yin J, Zhang Z, Wang X.
europepmc   +1 more source

B lymphocytes and tertiary lymphoid structures have a prognostic impact on penile squamous cell carcinoma. [PDF]

J Pathol Clin Res
Zavillová N, Waldauf P, Kendall Bártů M, Čapka D, Hojný J, Prouzová Z, Matěj R, Zachoval R, Hrudka J.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Ofatumumab and Granzyme B as immunotoxin against CD20 antigen

In Silico Pharmacology, 2022
Anti-CD20 antibodies such as ofatumumab has demonstrated efficacy in relapsed/refractory chronic lymphocytic leukemia, are among the most successful therapies to date. In this study, we have designed an immunotoxin composed of Granzyme B and the high affinity variant of Ofatumumab.
Fateme Sefid, Armina Alagheband Bahrami, Zahra Payandeh, Saeed Khalili, Ghasem Azamirad, Seyed Mehdy Kalantar, Maryam Touhidinia   +6 more
openaire   +2 more sources

Expression of CD20-specific chimeric antigen receptor (CD20-CAR) on Jurkat T cellsand evaluation its biological activity

Ministry of Science and Technology, Vietnam, 2022
CD20 is a potential target for immunotherapy treatments of haematological malignancies due to its specific expression and unique biological property. Over the years, many anti-CD20 monoclonal antibodies (mAbs) have been developed, such as Rituximab, Ibritumomab, Tositumomab, etc., and applied in B cells related to cancer treatments.
Nguyen Thanh Thao Vo, Dao Xuan Truc Chu, Dam Kim Tuyen Huynh, Thi Viet Anh Phung, Dang Quan Nguyen   +4 more
openaire   +1 more source

Development of a Mimotope-Based Vaccine Against CD20 Antigen

Protein & Peptide Letters, 2007
CD20, a B-cell-specific protein, is a primary target for immunotherapy of B-cell lymphomas. We used a mimotopes of CD20 to construct vaccines for B-cell-related disorders. The immunogenicity of the vaccines was tested in BALB/c mice. Results of this study suggest that the mimotope may be a useful tool for the construction of a functional vaccine to ...
Meng, Li, Wei, Han, Quiyang, Zhang, Xiaochang, Xue, Zenglu, Wang, Yingqi, Zhang   +5 more
openaire   +2 more sources

CD20: A target antigen for immunotherapy of autoimmune diseases

Autoimmunity Reviews, 2005
This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases.
PEROSA, Federico, FAVOINO, ELVIRA, PRETE, MARCELLA, Caragnano MA, Dammacco F.   +4 more
openaire   +3 more sources